185 related articles for article (PubMed ID: 36709639)
1. Systemic treatment with or without ablative therapies in oligometastatic breast cancer: A single institution analysis of patient outcomes.
Glemarec G; Lacaze JL; Cabarrou B; Aziza R; Jouve E; Zerdoud S; De Maio E; Massabeau C; Loo M; Esteyrie V; Ung M; Dalenc F; Izar F; Chira C
Breast; 2023 Feb; 67():102-109. PubMed ID: 36709639
[TBL] [Abstract][Full Text] [Related]
2. Ten-Year Outcomes of Stereotactic Body Radiotherapy for Oligometastatic Breast Cancer: Does Synchronous Oligometastatic Breast Cancer Benefit?
Nagpal SK; Khabra K; Ross G; Kirby AM
Clin Oncol (R Coll Radiol); 2023 Nov; 35(11):736-743. PubMed ID: 37684189
[TBL] [Abstract][Full Text] [Related]
3. Treatment Outcomes of Stereotactic Ablative Body Radiotherapy on Extra-cranial Oligometastatic and Oligoprogressive Breast Cancer: Mature Results from a Single Institution Experience.
Armstrong S; Makris A; Belessiotis-Richards K; Abdul-Latif M; Ostler P; Shah N; Miles D; Tsang YM
Clin Oncol (R Coll Radiol); 2024 Jun; 36(6):362-369. PubMed ID: 38575431
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
[TBL] [Abstract][Full Text] [Related]
5. Lung Metastases Treated With Stereotactic Ablative Radiation Therapy in Oligometastatic Colorectal Cancer Patients: Outcomes and Prognostic Factors After Long-Term Follow-Up.
Agolli L; Bracci S; Nicosia L; Valeriani M; De Sanctis V; Osti MF
Clin Colorectal Cancer; 2017 Mar; 16(1):58-64. PubMed ID: 27522627
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Definitive Stereotactic Body Radiotherapy and Outcomes in Adults With Extracranial Oligometastasis.
Poon I; Erler D; Dagan R; Redmond KJ; Foote M; Badellino S; Biswas T; Louie AV; Lee Y; Atenafu EG; Ricardi U; Sahgal A
JAMA Netw Open; 2020 Nov; 3(11):e2026312. PubMed ID: 33196810
[TBL] [Abstract][Full Text] [Related]
7. Role of Radiosurgery and Stereotactic Ablative Radiotherapy for Oligometastatic Non-Oncogene Addicted NSCLC.
Badellino S; Levis M; Cuffini EM; Cerrato M; Orlandi E; Chiovatero I; Aprile A; Gastino A; Cavallin C; Iorio GC; Parise R; Mantovani C; Ricardi U
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326616
[TBL] [Abstract][Full Text] [Related]
8. Patient and Treatment Factors Associated With Improved Local Control and Survival in Oligometastatic Bone Disease: Results From a Large Single-Institution Experience Using Stereotactic Body Radiation Therapy.
Thomas MC; Chen YH; Fite E; Pangilinan A; Bubelo K; Spektor A; Balboni TA; Huynh MA
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):747-761. PubMed ID: 35840113
[TBL] [Abstract][Full Text] [Related]
9. Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy.
Franzese C; Comito T; Toska E; Tozzi A; Clerici E; De Rose F; Franceschini D; Navarria P; Reggiori G; Tomatis S; Scorsetti M
Radiother Oncol; 2019 Apr; 133():220-226. PubMed ID: 30414754
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
[TBL] [Abstract][Full Text] [Related]
11. Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs.
Xu Q; Zhou F; Liu H; Jiang T; Li X; Xu Y; Zhou C
J Thorac Oncol; 2018 Sep; 13(9):1383-1392. PubMed ID: 29852232
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic body radiotherapy improves the survival of patients with oligometastatic non-small cell lung cancer.
Ouyang W; Yu J; Nuerjiang S; Li Z; Wang D; Wang X; Zhang J; Xie C
Cancer Med; 2019 Aug; 8(10):4605-4614. PubMed ID: 31245933
[TBL] [Abstract][Full Text] [Related]
13. Total tumor volume as a predictor of survival in patients with multiple oligometastases treated with stereotactic ablative radiotherapy (SABR).
Franzese C; Vernier V; Franceschini D; Comito T; Navarria P; Clerici E; Teriaca MA; Massaro M; Di Cristina L; Marini B; Galdieri C; Mancosu P; Tomatis S; Scorsetti M
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10495-10503. PubMed ID: 37280407
[TBL] [Abstract][Full Text] [Related]
14. Local ablative treatment for synchronous single organ oligometastatic lung cancer-A propensity score analysis of 180 patients.
Frost N; Tessmer A; Schmittel A; van Laak V; Raspe M; Ruwwe-Glösenkamp C; Brunn M; Senger C; Böhmer D; Ochsenreither S; Temmesfeld-Wollbrück B; Furth C; Schmidt B; Neudecker J; Rückert JC; Suttorp N; Witzenrath M; Grohé C
Lung Cancer; 2018 Nov; 125():164-173. PubMed ID: 30429016
[TBL] [Abstract][Full Text] [Related]
15. Impact of Medical Operability and Total Metastatic Ablation on Outcomes After SABR for Oligometastases.
Siva S; Jones G; Bressel M; Shaw M; Chander S; Chu J; Plumridge N; Byrne K; Kothari G; Hardcastle N; Gaudreault M; Kron T; Wheeler G; MacManus M; Hanna GG; Ball DL; David S
Int J Radiat Oncol Biol Phys; 2022 Dec; 114(5):862-870. PubMed ID: 35752407
[TBL] [Abstract][Full Text] [Related]
16. ATOM: A phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI.
Chan OSH; Lam KC; Li JYC; Choi FPT; Wong CYH; Chang ATY; Mo FKF; Wang K; Yeung RMW; Mok TSK
Lung Cancer; 2020 Apr; 142():41-46. PubMed ID: 32088604
[TBL] [Abstract][Full Text] [Related]
17. Local Ablative Therapy Combined with Pembrolizumab in Patients with Synchronous Oligometastatic Non-Small Cell Lung Cancer: A Recursive Partitioning Analysis.
Lee HI; Choi EK; Kim SS; Shin YS; Park J; Choi CM; Yoon S; Kim HR; Cho YH; Song SY
Int J Radiat Oncol Biol Phys; 2024 May; ():. PubMed ID: 38797499
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors in patients with oligometastatic breast cancer - A systematic review.
van Ommen-Nijhof A; Steenbruggen TG; Schats W; Wiersma T; Horlings HM; Mann R; Koppert L; van Werkhoven E; Sonke GS; Jager A
Cancer Treat Rev; 2020 Dec; 91():102114. PubMed ID: 33161237
[TBL] [Abstract][Full Text] [Related]
19. Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy.
Nicosia L; Cuccia F; Mazzola R; Ricchetti F; Figlia V; Giaj-Levra N; Rigo M; Tomasini D; Pasinetti N; Corradini S; Ruggieri R; Alongi F
Strahlenther Onkol; 2020 Sep; 196(9):813-820. PubMed ID: 32399637
[TBL] [Abstract][Full Text] [Related]
20. Recursive partitioning model-based analysis for survival of colorectal cancer patients with lung and liver oligometastases treated with stereotactic body radiation therapy.
Franzese C; Comito T; Franceschini D; Loi M; Clerici E; Navarria P; De Rose F; Di Brina L; Mancosu P; Reggiori G; Tomatis S; Scorsetti M
J Cancer Res Clin Oncol; 2020 May; 146(5):1227-1234. PubMed ID: 32056005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
